Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas; Departments of Pathology and Laboratory Medicine, and Microbiology and Immunology, Weill Cornell Medical College, New York, New York.
Center for Molecular and Translational Human Infectious Diseases Research, Department of Pathology and Genomic Medicine, Houston Methodist Research Institute and Houston Methodist Hospital, Houston, Texas.
Am J Pathol. 2021 Jun;191(6):983-992. doi: 10.1016/j.ajpath.2021.03.004. Epub 2021 Mar 16.
Since the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been international concern about the emergence of virus variants with mutations that increase transmissibility, enhance escape from the human immune response, or otherwise alter biologically important phenotypes. In late 2020, several variants of concern emerged globally, including the UK variant (B.1.1.7), the South Africa variant (B.1.351), Brazil variants (P.1 and P.2), and two related California variants of interest (B.1.429 and B.1.427). These variants are believed to have enhanced transmissibility. For the South Africa and Brazil variants, there is evidence that mutations in spike protein permit it to escape from some vaccines and therapeutic monoclonal antibodies. On the basis of our extensive genome sequencing program involving 20,453 coronavirus disease 2019 patient samples collected from March 2020 to February 2021, we report identification of all six of these SARS-CoV-2 variants among Houston Methodist Hospital (Houston, TX) patients residing in the greater metropolitan area. Although these variants are currently at relatively low frequency (aggregate of 1.1%) in the population, they are geographically widespread. Houston is the first city in the United States in which active circulation of all six current variants of concern has been documented by genome sequencing. As vaccine deployment accelerates, increased genomic surveillance of SARS-CoV-2 is essential to understanding the presence, frequency, and medical impact of consequential variants and their patterns and trajectory of dissemination.
自严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 大流行开始以来,人们一直关注具有增加传染性、增强逃避人体免疫反应能力或改变其他重要生物学表型的突变的病毒变异体的出现。2020 年末,几种令人关注的变异体在全球范围内出现,包括英国变异体 (B.1.1.7)、南非变异体 (B.1.351)、巴西变异体 (P.1 和 P.2) 以及两种加利福尼亚州相关的感兴趣变异体 (B.1.429 和 B.1.427)。这些变异体被认为具有增强的传染性。对于南非和巴西变异体,有证据表明刺突蛋白中的突变使其能够逃避一些疫苗和治疗性单克隆抗体。根据我们从 2020 年 3 月至 2021 年 2 月收集的 20,453 例 2019 年冠状病毒病患者样本的广泛基因组测序计划,我们报告了在休斯顿卫理公会医院(休斯顿,德克萨斯州)患者中发现所有这六种 SARS-CoV-2 变异体居住在大都市区。尽管这些变异体目前在人群中的相对频率(总计 1.1%)较低,但它们在地理上分布广泛。休斯顿是美国第一个通过基因组测序记录到所有六种当前令人关注的变异体在该地区持续传播的城市。随着疫苗的部署加速,对 SARS-CoV-2 的基因组监测至关重要,以了解相关变异体的存在、频率和对医疗的影响,以及它们的传播方式和轨迹。